ReViral Appoints Brett Haumann as Chief Medical Officer
ReViral Appoints Brett Haumann as Chief Medical Officer [...]
ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China
ReViral and LianBio Announce Exclusive Collaboration and License Agreement [...]
ReViral Raises $44 Million in Series C Financing
ReViral Raises $44 Million in Series C Financing [...]
ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection
ReViral Announces FDA Fast Track Designation Granted to Sisunatovir [...]
NETPark based ReViral wins multi-million investment for pioneering drug
NETPark based ReViral wins multi-million investment for pioneering drug [...]
NETPark based ReViral announces US$55 million series B fundraising to advance RSV clinical studies
NETPark based ReViral announces US$55 million series B fundraising [...]